Paliperidone
- Generic Name
- Paliperidone
- Brand Names
- Invega, Invega Hafyera, Xeplion, Niapelf, Byannli (previously Paliperidone Janssen-Cilag International), Trevicta (previously Paliperidone Janssen), ERZOFRI
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O3
- CAS Number
- 144598-75-4
- Unique Ingredient Identifier
- 838F01T721
- Background
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperido...
- Indication
As an oral extended-release tablet and a once-monthly extended-release suspension for intramuscular injection, paliperidone is indicated for the treatment of adults and adolescents with schizophrenia and in the treatment of schizoaffective disorder in combination with antidepressants or mood stabilizers. Paliperidone is also available in both an every-three-...
- Associated Conditions
- Schizoaffective Disorders, Schizophrenia
- Associated Therapies
- -
Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2013-07-08
- Lead Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
- Registration Number
- NCT01193166
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- First Posted Date
- 2010-07-07
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 450
- Registration Number
- NCT01157351
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 54
- Registration Number
- NCT01134731
- Locations
- 🇺🇸
UAB, Birmingham, Alabama, United States
Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 96
- Registration Number
- NCT00937261
- Locations
- 🇺🇸
UC Irvine, Irvine, California, United States
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 289
- Registration Number
- NCT00784238
Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2016-08-23
- Lead Sponsor
- Yale University
- Registration Number
- NCT00766064
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 491
- Registration Number
- NCT00761189
Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 387
- Registration Number
- NCT00761605
Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 190
- Registration Number
- NCT00761579
A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.
- Conditions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 407
- Registration Number
- NCT00668837
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.